PDF herunterladen
Horm Metab Res 2019; 51(12): 779-784
DOI: 10.1055/a-1039-1471
Review

Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?

Richard Straube
1   Zentrum für Apherese- und Hämofiltration am INUS Tagesklinikum – Cham, Germany
,
Gregor Müller
2   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
,
Karin Voit-Bak
1   Zentrum für Apherese- und Hämofiltration am INUS Tagesklinikum – Cham, Germany
,
Sergey Tselmin
2   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
,
Ulrich Julius
2   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
,
Ulrike Schatz
2   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
,
Hannes Rietzsch
2   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
,
Heinz Reichmann
3   Department of Neurology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
,
George P. Chrousos
2   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
4   University Research Institute of Maternal and Child Health & Precision Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Annette Schürmann
5   Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany
,
Luka Jarc
6   Center for Regenerative Therapies Dresden, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
,
Tjalf Ziemssen
3   Department of Neurology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
,
Timo Siepmann
3   Department of Neurology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
,
Stefan R. Bornstein
2   Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany
7   Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom
8   Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, University Hospital, Zürich, Switzerland
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

As the rate of obesity and the incidence of diabetes mellitus have been increasing, diabetic neuropathy has become the most common cause of peripheral neuropathy in developed countries. In addition, a variety of pathogenetically heterogeneous disorders can lead to impairment of the peripheral nervous system including amyloidosis, vitamin deficiencies, uremia and lipid disorders, alcohol abuse, autoimmune and infectious diseases as well as exposure to environmental toxins. We have noted that a combination of these disorders may aggravate the manifestations of peripheral diabetic neuropathy, an effect, which is most pronounced when metabolic and non-metabolic pathologies lead to cumulative damage. Current treatment options are limited and generally have unsatisfactory results in most patients. Therapeutic apheresis (INUSpherese®) allows the removal of metabolic, inflammatory, immunologic and environmental contributors to the disease process and may be an effective treatment option. We reviewed the developments in therapeutic apheresis for metabolic and non-metabolic peripheral neuropathy, including the current literature as well as data from our university diabetes center.

Key words

apheresis - neuropathy - lipids


Publikationsverlauf

Eingereicht: 01. Oktober 2019

Angenommen: 29. Oktober 2019

Artikel online veröffentlicht:
11. Dezember 2019

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hehir 2nd MK, Logigian EL. Infectious neuropathies. Continuum (Minneap Minn) 2014; 20: 1274-1292
    PubMedGoogle Scholar
  • 2 Gwathmey KG, Pearson KT. Diagnosis and management of sensory polyneuropathy. BMJ 2019; 365: l1108
    CrossrefPubMedGoogle Scholar
  • 3 Watson JC, Dyck PJ. Peripheral neuropathy: A practical approach to diagnosis and symptom management. Mayo Clin Proc 2015; 90: 940-951
    CrossrefPubMedGoogle Scholar
  • 4 Katona I, Weis J. Diseases of the peripheral nerves. Handb Clin Neurol 2017; 145: 453-474
    CrossrefPubMedGoogle Scholar
  • 5 Tesfaye S, Boulton AJ, Dyck PJ. et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293
    CrossrefPubMedGoogle Scholar
  • 6 Ziemssen T, Siepmann T. The investigation of the cardiovascular and sudomotor autonomic nervous system-a review. Front Neurol 2019; 10: 53
    CrossrefPubMedGoogle Scholar
  • 7 Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259-1270
    CrossrefPubMedGoogle Scholar
  • 8 Zochodne DW. The challenges of diabetic polyneuropathy: A brief update. Curr Opin Neurol 2019; 32: 66-675
    CrossrefPubMedGoogle Scholar
  • 9 Bonhof GJ, Herder C, Strom A. et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 2019; 40: 153-192
    CrossrefPubMedGoogle Scholar
  • 10 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: A 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
    Google Scholar
  • 11 Vinik AI. Clinical practice. Diabetic sensory and motor neuropathy. N Engl J Med 2016; 374: 1455-1464
    CrossrefPubMedGoogle Scholar
  • 12 Amour AA, Chamba N, Kayandabila J. et al. Prevalence, patterns, and factors associated with peripheral neuropathies among diabetic patients at tertiary hospital in the Kilimanjaro Region: Descriptive cross-sectional study from North-Eastern Tanzania. Int J Endocrinol 2019; 5404781
    PubMedGoogle Scholar
  • 13 Pai YW, Lin CH, Lin SY. et al. Reconfirmation of newly discovered risk factors of diabetic peripheral neuropathy in patients with type 2 diabetes: A case-control study. PLoS One 2019; 14: e0220175
    CrossrefPubMedGoogle Scholar
  • 14 Gokcay Canpolat A, Emral R, Keskin C. et al. Association of monocyte-to-high density lipoprotein-cholesterol ratio with peripheral neuropathy in patients with Type II diabetes mellitus. Biomark Med 2019; 13: 907-915
    CrossrefPubMedGoogle Scholar
  • 15 Zhen Q, Yao N, Chen X. et al. Total body adiposity, triglycerides, and leg fat are independent risk factors for diabetic peripheral neuropathy in chinese patients with type 2 diabetes mellitus. Endocr Pract 2019; 25: 270-278
    CrossrefPubMedGoogle Scholar
  • 16 Perez-Matos MC, Morales-Alvarez MC, Mendivil CO. Lipids: A suitable therapeutic target in diabetic neuropathy?. J Diabetes Res 2017; 2017: 6943851
    PubMedGoogle Scholar
  • 17 Othman A, Benghozi R, Alecu I. et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?. J Clin Lipidol 2015; 9: 568-575
    CrossrefPubMedGoogle Scholar
  • 18 Abraham A, Katzberg HD, Lovblom LE. et al. Uric acid levels correlate with sensory nerve function in healthy subjects. Can J Neurol Sci 2019; 46: 337-341
    CrossrefPubMedGoogle Scholar
  • 19 Singh AK, Kumar A, Karmakar D. et al. Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med 2013; 59: 253-257
    CrossrefPubMedGoogle Scholar
  • 20 Owhin SO, Adaja TM, Fasipe OJ. et al. Prevalence of vitamin B12 deficiency among metformin-treated type 2 diabetic patients in a tertiary institution, South-South Nigeria. SAGE Open Med 2019; 7: 2050312119853433
    CrossrefPubMedGoogle Scholar
  • 21 Alharbi TJ, Tourkmani AM, Abdelhay O. et al. The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. PLoS One 2018; 13: e0204420
    CrossrefPubMedGoogle Scholar
  • 22 Munukutla S, Pan G, Deshpande M. et al. Alcohol toxicity in diabetes and its complications: A double trouble?. Alcohol Clin Exp Res 2016; 40: 686-697
    CrossrefPubMedGoogle Scholar
  • 23 Staff NP, Windebank AJ. Peripheral neuropathy due to vitamin deficiency, toxins, and medications. Continuum (Minneap Minn) 2014; 20: 1293-1306
    PubMedGoogle Scholar
  • 24 Pizzorno J. Is the diabetes epidemic primarily due to toxins?. Integr Med (Encinitas) 2016; 15: 8-17
    PubMedGoogle Scholar
  • 25 Colbeth HL, Zeig-Owens R, Webber MP. et al. Post-9/11 peripheral neuropathy symptoms among world trade center-exposed firefighters and emergency medical service workers. Int J Environ Res Public Health 2019; 16: 1727
    CrossrefPubMedGoogle Scholar
  • 26 Straube R, Voit-Bak K, Gor A. et al. Lipid profiles in lyme borreliosis: a potential role for apheresis?. Horm Metab Res 2019; 51: 326-329
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Julius U, Tselmin S, Fischer S. et al. The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption. Atheroscler Suppl 2009; 10: 12-16
    CrossrefPubMedGoogle Scholar
  • 28 Kopprasch S, Graessler J, Bornstein SR. et al. Beyond lowering circulating LDL: Apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atheroscler Suppl 2009; 10: 34-38
    CrossrefPubMedGoogle Scholar
  • 29 Julius U, Taseva K, Fischer S. et al. Current situation of lipoprotein apheresis in Saxony. Atheroscler Suppl 2013; 14: 51-55
    CrossrefPubMedGoogle Scholar
  • 30 Feingold K, Grunfeld C, Lipoprotein Apheresis In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP. Eds Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000
    Google Scholar
  • 31 Isei T, Abe M, Nakanishi T. et al. The wound/burn guidelines - 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene. J Dermatol 2016; 43: 591-619
    CrossrefPubMedGoogle Scholar
  • 32 Weiss N. A critical review on the use of lipid apheresis and rheopheresis for treatment of peripheral arterial disease and the diabetic foot syndrome. Semin Dial 2012; 25: 220-227
    CrossrefPubMedGoogle Scholar
  • 33 Rietzsch H, Panzner I, Selisko T. et al. Heparin-induced Extracorporeal LDL Precipitation (H.E.L.P) in diabetic foot syndrome - preventive and regenerative potential?. Horm Metab Res 2008; 40: 487-490
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 34 Nishimura H, Enokida H, Sakamoto T. et al. Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. J Artif Organs 2018; 21: 378-382
    CrossrefPubMedGoogle Scholar
  • 35 Buzzigoli SB, Genovesi M, Lambelet P. et al. Plasmapheresis treatment in Guillain-Barre syndrome: potential benefit over intravenous immunoglobulin. Anaesth Intensive Care 2010; 38: 387-389
    CrossrefPubMedGoogle Scholar
  • 36 Sakai Y, Otsuka T, Tsuruoka S. A case of neuromyelitis optica spectrum disorder with early successful induction of double filtration plasmapheresis. Ther Apher Dial 2014; 18: 317-318
    CrossrefPubMedGoogle Scholar
  • 37 Muhlhausen J, Kitze B, Huppke P. et al. Apheresis in treatment of acute inflammatory demyelinating disorders. Atheroscler Suppl 2015; 18: 251-256
    CrossrefPubMedGoogle Scholar
  • 38 Teng D, Tan S, Yang M. et al. A case report of hepatitis B related optic neuritis treated with plasma exchange. Medicine (Baltimore) 2019; 98: e15432
    CrossrefPubMedGoogle Scholar
  • 39 Deschamps R, Gueguen A, Parquet N. et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol 2016; 263: 883-887
    CrossrefPubMedGoogle Scholar